Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 15/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17076844 | 0.81 | APP (0.43) | SCN10AOPRM1TGFBR1 | |
| SCHEMBL25767673 | 0.80 | AR (0.42) | ARANO1 | |
| SCHEMBL31633807 | 0.77 | PRKD1 (0.41) | SCN10AANO1OPRM1 | |
| SCHEMBL27061642 | 0.77 | PRKD1 (0.41) | SCN10AANO1OPRM1 | |
| SCHEMBL28292635 | 0.76 | SCN10A (0.44) | SCN10AARANO1 | |
| SCHEMBL30595907 | 0.76 | OPRM1 (0.42) | SCN10AAROPRM1 | |
| SCHEMBL24758227 | 0.75 | TSHR (0.44) | SCN10AARANO1OPRM1 | |
| SCHEMBL20652765 | 0.75 | ADORA3 (0.39) | SCN10AARTGFBR1 | |
| SCHEMBL2441972 | 0.75 | ADORA3 (0.39) | SCN10AANO1OPRM1TGFBR1 | |
| SCHEMBL2441973 | 0.75 | ADORA3 (0.39) | SCN10ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SCN10A 4560/4885AR 1806/4885ANO1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.